Stocks surge to new record highs

After a second vaccine for Covid-19 was announced, stocks surged, with America’s S&P 500 and the MSCI World Index both hitting record highs on Monday.

“Two vaccines are better than one,” says Tara Lachapelle on Bloomberg. This week brought positive news about trials of Moderna’s vaccine for Covid-19. The update gave global markets a profitable start to the week, with America’s S&P 500 and the MSCI World Index both hitting record highs on Monday. The FTSE 100 rose to its highest level since June and has gained more than 13% so far this month. 

A global bull market

The rally took a break the following day but, arguably, markets should be even more upbeat, says Nils Pratley in The Guardian. The Moderna vaccine is easier to store and transport than the Pfizer jab that made the headlines last week. 

That could speed up the daunting logistical challenges of rollout. For “airlines, events and hospitality… it really matters whether a vaccination programme takes six months, a year or more”. 

The bulls are out in force. Last week’s vaccine news triggered a $44.5bn flood of inflows into global stock funds, say Eric Platt and David Carnevali in the Financial Times. That is the biggest weekly inflow in “at least two decades”. 

American bulls are not finding many bargains, though. On a cyclically adjusted price/earnings ratio (Cape) of 31.26 the US market is currently more expensive than it has been for 96% of the time since 1881, says Mark Hulbert for marketwatch.com.

No wonder, then, that new research from Kevin Lansing, an adviser at the Federal Reserve Bank of San Francisco, suggests that US stocks are poised to “barely outperform inflation” over the coming decade. 

Value stocks will rise

The US stock rally is already showing “signs of exhaustion”, says Cormac Mullen on Bloomberg. The market’s heavy technology weighting helped the S&P 500 outperform most other major bourses this year through early September. Yet since then the US has underperformed the MSCI World Ex-USA Index by 4%. The baton has now passed to markets in Europe and Japan, which boast a bigger stable of value stocks (see page 20).

Since 2009 the MSCI USA Value Index has returned 246%, against 661% for the equivalent US growth index, says Jon Sindreu in The Wall Street Journal. Value seems due a catch-up rally, but history suggests that such periods don’t last very long. After their re-opening bounce, “old economy” shares are likely to face the same problems as before Covid-19: “ultra-low interest rates”, poor returns on equity and, for financial stocks, “strict banking regulation”. 

Vaccine news could bring higher interest rates than the market expects, says the Financial Times. Eye-watering valuations are partly the result of years of easy central-bank money. Yet US ten-year Treasury bond yields have been ticking up of late, reflecting falling bond prices. This suggests greater confidence that growth will return and long-term interest rates will rise. “Lower-for-longer” interest rates may not stay low for quite so long after all. 

Recommended

Are rights issues worth it?
Investment strategy

Are rights issues worth it?

Companies have been using rights issues to raise money from shareholders in record numbers this year. Should you chip in?
30 Nov 2020
Big Pharma deserves its reward for coming up with Covid-19 vaccines
Biotech stocks

Big Pharma deserves its reward for coming up with Covid-19 vaccines

Calls to restrain drug companies' profits from making Covid-19 vaccines are misplaced and would do more harm than good, says Matthew Lynn
29 Nov 2020
Bill Ackman: beware of short-term market volatility
Investment gurus

Bill Ackman: beware of short-term market volatility

Bill Ackman, founder of the Pershing Square hedge fund, is upbeat on prospects for markets in 2021, but is worried about short-term volatility as coro…
27 Nov 2020
More good news as AstraZeneca finds a third Covid vaccine
Biotech stocks

More good news as AstraZeneca finds a third Covid vaccine

Another week, another Covid-19 vaccine. This one from AstraZeneca and Oxford University is homegrown and ready to roll out fast. Matthew Partridge rep…
26 Nov 2020

Most Popular

The next 20 years: five new technologies on the horizon
Global Economy

The next 20 years: five new technologies on the horizon

What will everyday life be like in two decades’ time? Matthew Partridge peers into his crystal ball.
12 Nov 2020
This week’s rally in value stocks is just the beginning
Value investing

This week’s rally in value stocks is just the beginning

The arrival of a vaccine this week saw huge gains in the markets and investors switching out of big-tech growth stocks and into “value” stocks in more…
13 Nov 2020
Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
13 Nov 2020